Drugs Made In America Acquisition DMAA
NASDAQ DMAA
$10.91 +0.01 (+0.09%)
At close: Nov 13, 2026 · 4:00 PM EST

Drugs Made In America Acquisition (DMAA) Operating Expenses (2024 - 2026)

Updated

Analysis

Drugs Made In America Acquisition (DMAA) Operating Expenses (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Opex (Qtr)
1 BlackRock 189.07 Bn 145.60 Bn - 5.42 Bn
2 Spdr Gold Trust 125.11 Bn -432.90 Bn - 149.76 Mn
3 Brookfield 101.47 Bn -96.66 Bn - 13.46 Bn
4 Blackstone 91.35 Bn 85.56 Bn - 1.63 Bn
5 Kkr 87.89 Bn 54.59 Bn 1.76 Bn 3.72 Bn
6 Brookfield Asset Management 82.34 Bn 77.22 Bn - 915.00 Mn
7 Apollo Global Management 72.94 Bn 89.74 Bn 4.14 Bn 6.21 Bn
8 Wheaton Precious Metals 59.70 Bn 59.70 Bn 538.50 Mn 138.12 Mn
9 Ares Management 48.49 Bn 47.07 Bn 376.28 Mn 1.15 Bn
10 Drugs Made In America Acquisition 336.16 Mn 336.12 Mn - 136,934.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 136,934.00
Mar 31, 2026 143,301.00
Dec 31, 2025 2.09 Mn
Sep 30, 2025 263,703.00
Jun 30, 2025 131,919.00
Mar 31, 2025 330,925.00
Sep 30, 2024 199,859.00
API Access

Drugs Made In America Acquisition Operating Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-expenses&ticker=DMAA&period=max&api_key=YOUR_API_KEY